Advances in HR+/HER2– Breast Cancer: Current Clinical Perspectives

Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer remains the most common subtype, accounting for approximately 70% of all breast cancer diagnoses. Recent clinical advancements have centered on the integration of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and the emergence of antibody-drug conjugates (ADCs) to address treatment resistance. According to the American Cancer Society, the primary goal for patients with metastatic disease is to prolong progression-free survival while maintaining quality of life through targeted systemic therapies.

How CDK4/6 Inhibitors Have Reshaped Standard Care

The standard of care for patients with HR+/HER2– metastatic breast cancer now relies heavily on the combination of endocrine therapy and CDK4/6 inhibitors. Medications such as palbociclib, ribociclib, and abemaciclib work by inhibiting the proteins that drive tumor cell division. Data published in the New England Journal of Medicine indicates that these therapies significantly improve progression-free survival compared to endocrine therapy alone. Clinical practice has shifted toward identifying which patients derive the most benefit, with ongoing research focusing on biomarkers that predict resistance to these agents.

The Evolving Role of Antibody-Drug Conjugates

For patients who experience disease progression despite endocrine-based therapies, the treatment landscape is shifting toward antibody-drug conjugates. These “smart bombs” deliver chemotherapy directly to cancer cells by targeting specific proteins on the cell surface. The U.S. Food and Drug Administration (FDA) has approved therapies like trastuzumab deruxtecan for patients with “HER2-low” status—a classification that includes many patients previously categorized as HER2–. This development is significant because it expands the pool of patients eligible for targeted biological therapies rather than traditional, broad-spectrum chemotherapy.

Clinical Considerations for Treatment Sequencing

Determining the optimal sequence of therapies remains a primary challenge for oncologists. The National Comprehensive Cancer Network (NCCN) guidelines emphasize that treatment choices should be individualized based on tumor biology, the presence of visceral metastases, and the patient’s prior treatment history. While CDK4/6 inhibitors are typically used in the first-line setting, the subsequent use of agents like elacestrant—a selective estrogen receptor degrader (SERD)—is now recommended for patients with ESR1 mutations, as noted in trials reported by the American Society of Clinical Oncology.

Key Developments in HR+/HER2– Management

• Biomarker Testing: Routine testing for ESR1 mutations is becoming standard to guide the use of targeted endocrine therapies.
• HER2-Low Classification: Patients who previously tested negative for HER2 overexpression may now qualify for HER2-directed ADCs.
• Quality of Life: Current clinical trials prioritize the reduction of treatment-related toxicities, such as neutropenia and gastrointestinal distress, to improve patient adherence.

Future Directions in Breast Cancer Research

The next phase of clinical research focuses on overcoming acquired resistance to endocrine therapy. Researchers are investigating PI3K/AKT/mTOR pathway inhibitors and novel oral SERDs to provide more durable responses. As treatment options grow, the focus of the medical community remains on precision oncology—matching the specific molecular profile of a patient’s tumor to the most effective therapeutic agent. Future updates to clinical practice will likely emphasize earlier intervention with targeted agents to delay the need for cytotoxic chemotherapy.